Health Services Research & Development

Veterans Crisis Line Badge
Go to the ORD website
Go to the QUERI website

Assessment of Alternative Treatment Strategies for Chronic Genotype 1 Hepatitis C

Click for list of published reports
Click for topic nomination form
Click for list of reports in progress

Subscribe to the
ESP Report RSS feed RSS feed icon
Assessment of Alternative Treatment Strategies for Chronic Genotype 1 Hepatitis C (March 2013)

Principal Investigator: Jeremy D. Goldhaber-Fiebert, PhD
Investigators: Paul G. Barnett, PhD Sharon Dally, MS Steven M. Asch, MD, MPH Shan Liu, SM Lauren Cipriano, BSc, BA Douglas K. Owens, MD, MS
Research Associates: Isomi M. Miake-Lye, BA Jessica M. Beroes, BS

Evidence-based Synthesis Program (ESP) Center
West Los Angeles VA Medical Center

Washington (DC): Department of Veterans Affairs; March 2013

Download PDF: Complete Report, Executive Summary, Report, Appendices

Background

There is great potential to improve health outcomes for Veterans and other patients with chronic genotype 1 (GT1) Hepatitis C (HCV) infections through the use of newly-available directly acting antiviral (DAA) medications and patient genotyping (IL-28B). Chronic GT1 HCV infections have been historically difficult to treat with low cure rates on standard two drug therapy (Pegylated Interferon + Ribavirin), high rates of side-effects and treatment discontinuation, and low rates of uptake. Recently, FDA approved two DAAs (boceprevir and telaprevir). Used in combination with standard two drug therapy as triple therapy, these DAAs show higher rates of sustained viral response, though they are also more costly and have more severe side-effect profiles. IL-28B genotyping can help to identify patients least likely to respond to standard therapy and hence who stand to benefit the most from triple therapy and for whom, therefore, the increased risks of side-effects may be most justified.

To achieve the potential health benefits from DAAs and IL-28B genotyping while acknowledging very real budgetary and resource constraints, proactive planning supported by appropriate analyses is needed. VA added boceprevir to its formulary approximately a year ago, allows the use of telaprevir off formulary for a number of reasons, and has the capability to use IL-28B patient genotyping as well. Responding to a request for guidance submitted to the VA Evidence-based Synthesis Program (ESP), we undertook a set of preliminary studies aimed at providing rapid, timely estimates of cost, resource and health impacts of using DAAs and/or IL- 28B genotyping within VA over a 5 year time horizon.

Specifically, we addressed four related questions:

Key Question #1: What are the current usage patterns of directly acting antivirals and of IL-28B patient genotyping in the VA health system? And how do these patterns differ by VISN? Key Question #2: What will be the health impacts of using either of two available directly acting antivirals combined with pegylated interferon and ribavirin (triple therapy)? Key Question #3: How will the magnitudes of the health impacts measured in Question #2 change if IL-28B patient genotyping is used to offer triple therapy to those less likely to benefit from two-drug pegylated interferon + ribavirin? Key Question #4: What will be the cost and resource use patterns when using either triple therapy or IL-28B-guided triple therapy?

See also

Assessment of Alternative Treatment Strategies for Chronic Genotype 1 Hepatitis C: A Systematic Review (Management eBrief)